Quick Answer
MoonLake Immunotherapeutics reported Total Assets of $424.43 million for fiscal year 2025.
MoonLake Immunotherapeutics Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $424.43M | -11.2% |
| 2024 | $477.93M | -9.2% |
| 2023 | $526.54M | +585.2% |
| 2022 | $76.84M | +693.6% |
| 2021 | $9.68M | -91.7% |
| 2020 | $116.63M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $414.33M | -20.0% | -9.9% |
| June 30, 2025 | $460.10M | -15.6% | -10.0% |
| March 31, 2025 | $511.26M | -9.4% | +7.0% |
| December 31, 2024 | $477.93M | -9.2% | -7.8% |
| September 30, 2024 | $518.21M | +3.6% | -4.9% |
| June 30, 2024 | $544.88M | +7.6% | -3.4% |
| March 31, 2024 | $564.12M | +744.5% | +7.1% |
| December 31, 2023 | $526.54M | +585.2% | +5.3% |
- MoonLake Immunotherapeutics showed a decrease of -11.2% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, MoonLake Immunotherapeutics’s total assets has grown by 263.9% (from $116.63 million to $424.43 million).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: